Table 1.
Patient characteristics.
| Baseline characteristics | Arm 1: AAP (n = 39) | Arm 2: AAP + D (n = 41) | Arm 3: D (n = 42) | All cohorts(n = 122) |
|---|---|---|---|---|
| Age (yr) | 64 (43–83) | 65 (53–74) | 66 (46–78) | 65 (43–83) |
| Race Black or African American White Unknown |
4 (10) 35 (90) 0 (0) |
6 (15) 33 (80) 2 (5) |
3 (7) 39 (93) 0 (0) |
13 (11) 107 (88) 2 (1) |
| Laboratory values | ||||
| PSA (ng/ml) Testosterone ng/dl Albumin (g/dl) Alkaline phosphatase (units/l) LDH (units/l) Hemoglobin (g/dl) |
3.1 (1.2–35.4) 352 (162–739) 4.3 (3.3–4.8) 66 (29–134) 170 (96–554) 14.3 (12.3–18.9) |
5.8 (1.2–45.1) 318 (176–841) 4.3 (3.5–5.0) 66 (36–111) 170 (135–459) 14.3 (11.9–16.6) |
4.1 (1.0–48.3) 355.5 (151–904) 4.3 (3.4–4.9) 70 (42–139) 173 (121–539) 14.2 (12.4–17.2) |
4.4 (1.0–48.3) 331 (151–904) 4.3 (3.3–5.0) 67 (29–134) 170 (96–554) 14.3 (11.9–18.9) |
| ECOG performance status 1 0 |
4 (10) 35 (90) |
2 (5) 39 (95) |
3 (7) 39 (93) |
9 (7) 113 (93) |
| Prostatectomy Gleason score Unknown Total Gleason score 6 or 7 Total Gleason score ≥8 |
2 (5.1) 20 (51.3) 17 (43.6) |
– 22 (53.7) 19 (46.3) |
– 25 (59.5) 17 (40.5) |
2 (1.6) 67 (54.9) 53 (43.4) |
| TNM stage Unknown pT1-T2 N0 or NX pT3a N0 or NX pT3a N1 pT3b N0 or NX pT3b N1 pT4 NX |
2 (5) 8 (21) 13 (33) 2 (5) 10 (26) 3 (8) 1 (3) |
1 (2) 21 (51) 11 (27) 0 (0) 6 (15) 2 (5) 0 (0) |
2 (5) 18 (43) 9 (21) 1 (2) 10 (34) 2 (5) 0 (0) |
5 (4) 47 (39) 33 (27) 3 (2) 26 (21) 7 (6) 1 (1) |
| Prior therapies Salvage radiation therapy |
23 (59) |
24 (59) |
27 (64) |
74 (61) |
AAP = abiraterone acetate plus prednisone; D = degarelix; ECOG = Eastern Cooperative Oncology Group; LDH = lactate dehydrogenase; PSA = prostate-specific antigen; TNM = tumor node metastasis.
Data are given as n (%) or median (range).